Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest. Latest Ratings for KZR Date Firm Action From To Dec 2021 Wells Fargo Initiates Coverage On Overweight Nov 2021 HC Wainwright & Co. Maintains Buy Jul 2021 JonesTrading Initiates Coverage On Buy View More Analyst Ratings for KZR View the Latest Analyst Ratings read more